Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma
- PMID: 11328532
- DOI: 10.1046/j.1440-1827.2001.01182.x
Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma
Abstract
Expression of hepatocyte growth factor (HGF) and c-Met (HGF receptor) has been reported in many neoplasms. We investigated coexpression of HGF and c-Met to determine the role of the HGF/c-Met pathway in breast carcinoma, especially at the cancer front. Eighty-eight cases of carcinoma of the breast were studied by immunohistochemistry and by in situ hybridization for HGF and c-Met expression. The staining pattern was termed "front accentuation pattern" when it was most conspicuous at the cancer front. HGF and c-Met proteins were expressed in cancer and stromal cells, with autocrine and paracrine patterns. The front accentuation pattern of c-Met was observed in cancer cells, but not in stromal cells. The front accentuation pattern was not observed in HGF. Coexpression of HGF and c-Met at the cancer front was correlated with histologic grade, reduced patient survival and a high Ki-67 labeling index. Our findings suggest that the HGF/c-Met pathway acts primarily as a mitogen, especially at the cancer front, in a paracrine manner and affects some clinical factors, including patient survival.
Similar articles
-
Functional expression of HGF and its receptor in human colorectal cancer.Digestion. 2000;61(4):237-46. doi: 10.1159/000007764. Digestion. 2000. PMID: 10878450
-
[Expression of hepatocyte growth factor/c-Met system in nasopharyngeal carcinoma and its biological significance].Zhonghua Bing Li Xue Za Zhi. 2005 Feb;34(2):75-9. Zhonghua Bing Li Xue Za Zhi. 2005. PMID: 15842800 Chinese.
-
Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma.Am J Pathol. 1996 Jan;148(1):225-32. Am J Pathol. 1996. PMID: 8546209 Free PMC article.
-
The hepatocyte growth factor regulatory factors in human breast cancer.Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):202-11. doi: 10.1158/1078-0432.ccr-0553-3. Clin Cancer Res. 2004. PMID: 14734471
-
The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer.Can J Physiol Pharmacol. 2002 Feb;80(2):91-102. doi: 10.1139/y02-010. Can J Physiol Pharmacol. 2002. PMID: 11934261 Review.
Cited by
-
Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.Mol Cancer Ther. 2019 Feb;18(2):399-412. doi: 10.1158/1535-7163.MCT-18-0710. Epub 2018 Dec 5. Mol Cancer Ther. 2019. PMID: 30518672 Free PMC article.
-
Systematic analysis of NLMP suggests nuclear localization of RTK/MET kinases resemble cancer cell clearance.J Exp Clin Cancer Res. 2019 Jan 30;38(1):43. doi: 10.1186/s13046-018-1004-z. J Exp Clin Cancer Res. 2019. PMID: 30700325 Free PMC article.
-
High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer.Breast Cancer Res. 2020 Mar 18;22(1):30. doi: 10.1186/s13058-020-01266-x. Breast Cancer Res. 2020. PMID: 32188473 Free PMC article.
-
Adipocytes in Breast Cancer, the Thick and the Thin.Cells. 2020 Feb 27;9(3):560. doi: 10.3390/cells9030560. Cells. 2020. PMID: 32120856 Free PMC article. Review.
-
Recent developments in receptor tyrosine kinases targeted anticancer therapy.Vet World. 2016 Jan;9(1):80-90. doi: 10.14202/vetworld.2016.80-90. Epub 2016 Jan 29. Vet World. 2016. PMID: 27051190 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous